Important note: Information in this article was accurate in 1997. The state of the art may have changed since the publication date.
PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Monday August 25 7:00 PM EDT
The decision was based on recent data from clinical trials using Zerit in adults and children which demonstrate that combinations that include d4T can reduce viral load, often to undetectable levels, and increase the body's infection-fighting CD4 cells. Both are proven markers of disease improvement.
Bristol-Myers Squibb is one of the leading companies in the research and development of HIV treatments. In addition to Zerit, the company markets VIDEX(R) (didanosine), also known as ddI, for treating HIV. Bristol-Myers Squibb is also developing two protease inhibitors for the treatment of HIV.
Zerit has been available in the U.S. since June 1994 and in Europe since May 1996, and is available in several other countries worldwide. In the U.S., Zerit is indicated for the treatment of HIV-infected patients who have received prolonged prior AZT (zidovudine) therapy. The most notable clinical toxicity of Zerit is peripheral neuropathy, which usually resolves if treatment is withdrawn. Resumption of treatment may be considered at a reduced dose.
VIDEX has been on the market in the U.S. since 1991 and is available worldwide. VIDEX is indicated for the first-line treatment of HIV infection when antiretroviral therapy is warranted. The most common adverse events associated with VIDEX are diarrhea and peripheral neuropathy. Both Zerit and VIDEX are now available for the treatment of children with AIDS.
Bristol-Myers Squibb also markets TAXOL(R) (paclitaxel) injection for AIDS-related Kaposi's sarcoma, Megace(R) (megestrol acetate) Oral Suspension for HIV anorexia/cachexia, and Fungizone(R) (amphotericin B) Oral Suspension for oral candidiasis in HIV-infected patients.
Bristol-Myers Squibb is a diversified worldwide health and personal care company whose principal businesses are pharmaceuticals, consumer products, nutritional and medical devices. It is a leading maker of innovative therapies for cardiovascular, metabolic and infectious diseases, central nervous system and dermatological disorders, and cancer. The company is a leader in consumer medicines, orthopaedic devices, ostomy care, wound management, nutritional supplements, infant formulas, and hair and skin products.
Visit Bristol-Myers Squibb on the World Wide Web at : http:/www.bms.com
SOURCE: Bristol-Myers Squibb Company
Copyright (c) 1997/PR NewsWire. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Permissions Desk, PR Newswire, 810 Seventh Avenue, New York, NY 10019.
970825
PR970817
Copyright © 1997 - PRNewswire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through PRNewswire, Permissions, 810 Seventh Ave., 32nd Floor, New York, NY 10019 http://www.prnewswire.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, National Library of Medicine, and donations from users like you.
Always watch for outdated information. This article first appeared in 1997. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 1997. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .